EVO
Evotec SE
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · DE
$1.86
−2.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 719.9M | 757.3M | 797.0M | 781.4M | 751.4M |
| Cost of Revenue | 645.4M | 694.6M | 682.1M | 606.4M | 577.4M |
| Gross Profit | 74.5M | 62.7M | 114.9M | 175.1M | 174.1M |
| Operating Expenses | |||||
| R&D Expense | 39.1M | 74.3M | 50.9M | 68.5M | 76.6M |
| SG&A Expense | 170.7M | 123.6M | 188.2M | 169.6M | 156.2M |
| General & Admin Expense | — | — | 170.7M | 152.7M | 142.7M |
| Selling & Marketing Expense | — | — | 17.5M | 16.9M | 13.5M |
| Other Expenses | (6.6M) | — | 18.3M | (15.6M) | (79.6M) |
| Total Operating Expenses | 203.2M | 198.0M | 257.4M | 222.6M | 153.2M |
| Cost and Expenses | 848.6M | 892.6M | 939.5M | 828.9M | 730.6M |
| Operating Income (EBIT) | (128.8M) | (135.3M) | (142.5M) | (47.5M) | 20.9M |
| Non-Operating | |||||
| Interest Income | 4.0M | 4.2M | 2.4M | 9.3M | 8.3M |
| Interest Expense | 11.7M | 13.9M | 11.7M | 11.7M | 13.2M |
| Net Interest Income | (7.7M) | (9.6M) | (9.3M) | (2.5M) | (4.8M) |
| Other Non-Op Income/Expense | (58.1M) | 12.0M | (51.5M) | (33.1M) | (174.8M) |
| Non-Operating Income (excl Interest) | 54.8M | (25.9M) | 39.8M | 21.3M | 161.7M |
| EBT (Pre-Tax Income) | (186.9M) | (123.3M) | (194.0M) | (80.6M) | (154.0M) |
| Income Tax Expense | 13.1M | (23.9M) | 2.1M | 3.3M | 21.7M |
| Bottom Line | |||||
| Net Income | (200.0M) | (99.4M) | (196.1M) | (83.9M) | (175.7M) |
| Earnings from Cont. Ops | (200.0M) | (99.4M) | (196.1M) | (83.9M) | (175.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (200.0M) | (99.4M) | (196.1M) | (83.9M) | (175.7M) |
| Per Share | |||||
| Basic EPS | ($0.56) | ($0.28) | ($0.56) | ($0.23) | ($0.49) |
| Diluted EPS | ($0.56) | ($0.28) | ($0.56) | ($0.23) | ($0.49) |
| Revenue Per Share | $2.02 | $2.13 | $2.26 | $2.21 | $2.13 |
| Shares | |||||
| Basic Shares Outstanding | 355.5M | 355.2M | 353.3M | 353.9M | 353.3M |
| Diluted Shares Outstanding | 355.5M | 355.2M | 354.6M | 353.9M | 353.4M |
| Profitability Metrics | |||||
| EBITDA | (85.6M) | (13.9M) | (80.7M) | 24.1M | (57.6M) |
| D&A | 98.0M | 95.5M | 101.6M | 93.0M | 83.2M |
| EBIT | (183.6M) | (109.4M) | (182.3M) | (68.9M) | (140.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026